Akero Therapeutics, Inc. has reported its financial results for the second quarter of 2025 and provided an update on its business operations. The company's cash, cash equivalents, and short and long-term marketable securities stood at $1,086.2 million as of June 30, 2025. This is a significant increase from the previous period, indicating a strong financial position.
In terms of expenses, research and development expenses for the three-month period ending June 30, 2025, were reported at $69.3 million, compared to $55.3 million for the same period in 2024. This increase was primarily due to higher expenses associated with ongoing phase 3 studies, manufacturing clinical supplies, and personnel-related costs. Similarly, general and administrative expenses for the same period in 2025 were $11.6 million, compared to $10.4 million in 2024, attributed to higher personnel, professional services, and other operating costs.
The company is confident in its financial stability, believing that its cash, cash equivalents, and short and long-term marketable securities will be adequate to fund its current operating plan into 2028.
Akero Therapeutics also highlighted significant milestones achieved in its clinical programs, particularly the publication of data from the phase 2b symmetry study in the New England Journal of Medicine. This publication reinforces the potential of its lead product candidate, efruxifermin (efx), as a first* and best-in-class therapy with disease-modifying activity in advanced-stage metabolic dysfunction-associated steatohepatitis (MASH).
Data presented at the EASL Congress 2025 further demonstrated the potential of efx in reversing cirrhosis in high-need MASH subgroups, indicating its broad potential in late-breaking oral presentations. Additionally, insights from the phase 2b harmony study showcased efx's ability to improve fibrosis in pre-cirrhotic MASH, with a majority of patients treated with efx showing improvements across various measures of antifibrotic response.
As a result of these announcements, the company's shares have moved -4.43% on the market, and are now trading at a price of $50.45. If you want to know more, read the company's complete 8-K report here.
